US panel endorses Savient's gout therapy pegloticase
This article was originally published in Scrip
Executive Summary
The US FDA's arthritis advisory committee has overwhelmingly endorsed licensing of Savient Pharmaceuticals' Krystexxa (pegloticase) for treatment-failure gout, but recommended restricting distribution through a mandatory patient registry and conducting postmarketing studies to monitor for cardiovascular adverse events.